Skip to content
ppharmaranks
Menu
Class IIOngoing

DOBUTamine Injection recall

FDA recall D-0489-2025 · initiated May 28, 2025

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jul 2, 2025How we research

Pfizer Inc. recalled DOBUTamine Injection in May 2025 — an FDA Class II recall (D-0489-2025) because Discoloration; discolored solution from cracked vials.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Discoloration; discolored solution from cracked vials

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot KA5023, exp 02/28/2026

Quantity recalled: 98,410 vials

Details

Product
DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial, carton of 10 Fliptop Vials, Rx only, For Intravenous Use Only, Made in Italy, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA. NDC Carton: 0409-2344-02; NDC Vial: 0409-2344-62
Recalling company
Pfizer Inc
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide in the USA
Initiated
May 28, 2025
FDA report date
Jul 2, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was DOBUTamine Injection recalled?
Pfizer Inc. recalled DOBUTamine Injection in May 2025 — an FDA Class II recall (D-0489-2025) because Discoloration; discolored solution from cracked vials. May cause temporary or medically reversible harm; low probability of serious harm.
Why was DOBUTamine Injection recalled?
Per the FDA enforcement record, the reason for recall D-0489-2025 was: Discoloration; discolored solution from cracked vials
Is a recalled DOBUTamine Injection dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of DOBUTamine Injection are affected?
Distributed: Nationwide in the USA. The recall covers these lots — Lot KA5023, exp 02/28/2026. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0489-2025.

Source: openFDA Drug Enforcement record D-0489-2025

← All drug recalls